Skip to main content

Table 1 Characteristics of healthy volunteers and patients with breast cancer

From: Circulating cell-free DNA-based epigenetic assay can detect early breast cancer

 

Whole set (n = 278)

Training set (n = 167)

Validation set (n = 111)

Number of samples

HVs

133

80

53

Patients with BC

145

87

58

Mean age (range)

HVs

45.3 (22–70)

45.8 (26–70)

44.5 (22–66)

Patients with BC

59.5 (36–81)

59.8 (36–81)

59.1 (36–81)

Subtype

Luminal

98

58

40

Triple-negative

25

14

11

HER2

10

6

4

Luminal HER2

8

6

2

not assessed (DCIS)

4

3

1

Stage

0

4

3

1

I

47

27

20

IIA

31

19

12

IIB

22

11

11

III

9

8

1

IV

32

19

13

Early BC (Stage0-I)

Luminal

36

22

14

Triple-negative

8

3

5

HER2

2

2

0

Luminal HER2

1

0

1

not assessed (DCIS)

4

3

1

  1. HVs healthy volunteers, BC breast cancer, HER2 human epidermal growth factor receptor 2, DCIS ductal carcinoma in situ, Subtype immunohistochemically categorized subtype